These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18178782)

  • 41. Effects of NADPH oxidase inhibitor on diabetic nephropathy in OLETF rats: the role of reducing oxidative stress in its protective property.
    Nam SM; Lee MY; Koh JH; Park JH; Shin JY; Shin YG; Koh SB; Lee EY; Chung CH
    Diabetes Res Clin Pract; 2009 Feb; 83(2):176-82. PubMed ID: 19111363
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Oral antidiabetics, pacifiers for doctor and patient].
    Erkelens DW
    Ned Tijdschr Geneeskd; 1983 Dec; 127(52):2380-1. PubMed ID: 6656939
    [No Abstract]   [Full Text] [Related]  

  • 43. Intensive therapy of type 2 diabetes (ACCORD trial) (OCTOBER 2008).
    Drake JW
    Cleve Clin J Med; 2009 Feb; 76(2):83; author reply 83-4. PubMed ID: 19188471
    [No Abstract]   [Full Text] [Related]  

  • 44. Renal status among patients using metformin in a primary care setting.
    Kennedy L; Herman WH;
    Diabetes Care; 2005 Apr; 28(4):922-4. PubMed ID: 15793196
    [No Abstract]   [Full Text] [Related]  

  • 45. Nephropathy in type 2 diabetes.
    Mora C; Garcia J; Navarro JF
    N Engl J Med; 2000 Feb; 342(6):441; author reply 442. PubMed ID: 10681230
    [No Abstract]   [Full Text] [Related]  

  • 46. Predictive value of interleukin-10 promoter genotypes and haplotypes in determining the susceptibility to nephropathy in type 2 diabetes patients.
    Mtiraoui N; Ezzidi I; Kacem M; Ben Hadj Mohamed M; Chaieb M; Haj Jilani AB; Mahjoub T; Almawi WY
    Diabetes Metab Res Rev; 2009 Jan; 25(1):57-63. PubMed ID: 19031431
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Update in diabetes management.
    Cranwell-Bruce LA
    Medsurg Nurs; 2009; 18(1):51-3; quiz 54. PubMed ID: 19331300
    [No Abstract]   [Full Text] [Related]  

  • 48. Oral antidiabetes medication adherence and health care utilization among Medicaid-enrolled type 2 diabetic patients beginning monotherapy.
    Shenolikar RA; Balkrishnan R
    Diabetes Care; 2008 Feb; 31(2):e5. PubMed ID: 18227463
    [No Abstract]   [Full Text] [Related]  

  • 49. Changing the diabetes treatment paradigm.
    Hirsch R
    Arch Intern Med; 2009 Jul; 169(13):1246; author reply 1247. PubMed ID: 19597080
    [No Abstract]   [Full Text] [Related]  

  • 50. Do diabetes drugs modify the risk of pancreatic cancer?
    Yang YX
    Gastroenterology; 2009 Aug; 137(2):412-5. PubMed ID: 19563838
    [No Abstract]   [Full Text] [Related]  

  • 51. Oral hypoglycaemics for diabetes: when and which?
    Drug Ther Bull; 1991 Feb; 29(4):13-6. PubMed ID: 1935599
    [No Abstract]   [Full Text] [Related]  

  • 52. Electrolytes and NA(+)-K(+)-ATPase: potential risk factors for the development of diabetic nephropathy.
    Shahid SM; Mahboob T
    Pak J Pharm Sci; 2008 Apr; 21(2):172-9. PubMed ID: 18390448
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of urolithiasis: a link between stone formation and diabetes mellitus?
    Zimmerer T; Weiss C; Hammes HP; Braun C; Hesse A; Alken P; Knoll T
    Urol Int; 2009; 82(3):350-5. PubMed ID: 19440027
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diabetic cardiovascular disease lost in translation between endocrinology and cardiology.
    Dagdelen S
    Am J Cardiol; 2008 Oct; 102(8):1115-6. PubMed ID: 18929722
    [No Abstract]   [Full Text] [Related]  

  • 56. Study of insulin resistance in relation to serum IGF-I levels in treated type-II diabetic patients.
    Srinivas M; Narayana P; Surender T; Krishna DR
    J Assoc Physicians India; 2008 Aug; 56():645-6. PubMed ID: 19054866
    [No Abstract]   [Full Text] [Related]  

  • 57. [Reduced neuropathic risk via enhanced glucose control?].
    Ziegler D
    Dtsch Med Wochenschr; 2013 Mar; 138(11):513. PubMed ID: 23463469
    [No Abstract]   [Full Text] [Related]  

  • 58. [Recommendations for the drug therapy of diabetes type 2. Treatment of associated vascular risk factors. French Agency for the Safety of Therapeutic Products].
    Presse Med; 1999 Oct; 28(29):1584-9. PubMed ID: 10544712
    [No Abstract]   [Full Text] [Related]  

  • 59. [Nihilism or polyteism in diabetic care?].
    Linnersten L
    Lakartidningen; 2008 May 7-13; 105(19):1415. PubMed ID: 18574987
    [No Abstract]   [Full Text] [Related]  

  • 60. Letter to the Editor - "longitudinal effects of depression and glycemic control in veterans with type 2 diabetes" by Richardson et al.
    Faulkner J
    Gen Hosp Psychiatry; 2009; 31(3):300. PubMed ID: 19410115
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.